IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN MULTIPLE RECALL/REFRACTORY MYELOMA (MMRR): ANALYSIS OF HIGH-RISK PATIENT SUBGROUPS (PTS) FROM THE KARMMA STUDY

被引：0

作者：

Jesus, San-Miguel ^{[1
]}

Noopur, Raje S. ^{[2
]}

David, Siegel ^{[3
]}

Sundar, Jagannath ^{[4
]}

Sagar, Lonial ^{[5
]}

Nikhil, Munshi C. ^{[6
,7
]}

Philippe, Moreau ^{[8
]}

Hartmut, Goldschmidt ^{[9
,10
]}

Michele, Cavo ^{[11
]}

Anna, Truppel-Hartmann ^{[12
]}

Everton, Rowe ^{[13
]}

Huang Liping ^{[13
]}

Amit, Agarwal ^{[13
]}

Julie, Wang ^{[13
]}

Timothy, Campbell B. ^{[13
]}

Donna, Reece E. ^{[14
]}

机构：

[1] Clin Univ Navarra, Pamplona, Spain

[2] Hosp Gen Massachusetts, Boston, MA 02114 USA

[3] Ctr Med Univ Hackensack, Hackensack, NJ USA

[4] Mt Sinai Hosp, New York, NY 10029 USA

[5] Escuela Med Emory, Atlanta, GA USA

[6] Harvard Med Sch, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA

[7] Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

[8] Ctr Hosp Univ Nantes, Nantes, France

[9] Hosp Univ Heidelberg, Heidelberg, Germany

[10] Natl Ctr Tumor Dis, Heidelberg, Germany

[11] Bologna Univ, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[12] Bluebird Bio, Cambridge, MA USA

[13] Bristol Myers Squibb, Princeton, NJ USA

[14] Ctr Oncol Princess Margaret, Toronto, ON, Canada

来源：

HAEMATOLOGICA | 2021年 / 106卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

CO-069

引用

页码：77 / 77

页数：1

共 50 条

[1] Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study
Raje, Noopur S.
Siegel, David S.
Jagannath, Sundar
Lonial, Sagar
Munshi, Nikhil C.
Moreau, Philippe
Goldschmidt, Hartmut
Cavo, Michele
Truppel-Hartmann, Anna
Rowe, Everton
Huang, Liping
Agarwal, Amit
Wang, Julie
Campbell, Timothy B.
San-Miguel, Jesus F.
Reece, Donna E.
BLOOD, 2020, 136
[2] Idecabtagene vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study
Goldschmidt, Hartmut
Raje, Noopur
Siegel, David
Jagannath, Sundar
Lonial, Sagar
Munshi, Nikhil
Moreau, Philippe
Cavo, Michele
Truppel-Hartmann, Anna
Rowe, Everton
Huang, Liping
Agarwal, Amit
Wang, Julie
Campbell, Timothy
San-Miguel, Jesus
Reece, Donna
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 50 - 50
[3] Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of high-risk patient (Pt) subgroups in the KarMMa study
Goldschmidt, H.
Raje, N. S.
Siegel, D.
Jagannath, S.
Lonial, S.
Munshi, N. C.
Moreau, P.
Cavo, M.
Truppel-Hartmann, A.
Rowe, E.
Huang, L.
Agarwal, A.
Wang, J.
Campbell, T. B.
San-Miguel, J.
Reece, D. E.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 18 - 19
[4] EFFECTIVENESS AND SAFETY OF IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN OLDER PATIENTS WITH MULTIPLE RECRACING / REFRACTORY MYELOMA (MMRR): SUBGROUP ANALYSIS OF THE KARMMA STUDY
Paula, Rodriguez-Otero
Jesus, Berdeja
Noopur, Raje
David, Siegel
Yi, Lin
Larry, Anderson D.
Salomon, Manier
Hermann, Einsele
Michele, Cavo
Anna, Truppel-Hartmann
Everton, Rowe
Jill, Sanford
Julie, Wang
Timothy, Campbell B.
Sundar, Jagannath
HAEMATOLOGICA, 2021, 106 (10) : 76 - 76
[5] KARMMA STUDY: CHARACTERIZATION OF CYTOKINE RELEASE SYNDROME (CRS) IN PATIENTS (PTS) WITH MULTIPLE RELAPSE/REFRACTORY MYELOMA (MMRR) TREATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121)
Albert, Oriol
Ankit, Kansagra
Yi, Lin
Jesus, Berdeja
Nina, Shah
Ibrahim, Yakoub-Agha
Hermann, Einsele
Alessandro, Rambaldi
Anna, Truppel-Hartmann
Everton, Rowe
Julie, Wang
Amit, Agarwal
Timothy, Campbell B.
Sagar, Lonial
HAEMATOLOGICA, 2021, 106 (10) : 77 - 78
[6] Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma
Kansagra, Ankit
Lin, Yi
Berdeja, Jesus G.
Shah, Nina
Oriol, Albert
Yakoub-Agha, Ibrahim
Einsele, Hermann
Rambaldi, Alessandro
Truppel-Hartmann, Anna
Rowe, Everton
Wang, Julie
Agarwal, Amit
Campbell, Timothy B.
Lonial, Sagar
BLOOD, 2020, 136
[7] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A CAR T THERAPY TARGETING BCMA, IN PATIENTS WITH MULTIPLE RECLAIMER/REFRACTORY MYELOMA (MMRR): UPDATE FROM THE KarMMa STUDY
Albert, Oriol
Jesus, San-Miguel
Ankit, Kansagra
Deepu, Madduri
Nina, Shah
Philippe, Moreau
Ibrahim, Yakoub-Agha
Michel, Delforge
Michele, Cavo
Hermann, Einsele
Hartmut, Goldschmidt
Katja, Weisel
Alessandro, Rambaldi
Donna, Reece
Paula, Rodriguez-Otero
Fabio, Petrocca
Jamie, Connarn N.
Payal, Patel
Huang Liping
Timothy, Campbell B.
Kristen, Hege
Nikhil, Munshi C.
HAEMATOLOGICA, 2021, 106 (10) : 76 - 77
[8] Efficacy and Safety of Idecabtagene vicleucel (ide-cel, bb2121) in Elderly Patients (Pts) with Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa Subgroup Analysis
Einsele, Hermann
Berdeja, Jesus
Raje, Noopur
Siegel, David
Lin, Yi
Anderson, Larry, Jr.
Rodriguez-Otero, Paula
Manier, Salomon
Cavo, Michele
Truppel-Hartmann, Anna
Rowe, Everton
Sanford, Jill
Wang, Julie
Campbell, Timothy
Jagannath, Sundar
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 53 - 53
[9] Efficacy and safety of Idecabtagene Vicleucel (ide-cel, bb2121) in elderly patients (Pts) with relapsed and refractory multiple myeloma (RRMM): KarMMa subgroup analysis
Einsele, H.
Berdeja, J.
Raje, N. S.
Siegel, D. S.
Lin, Y.
Anderson, L. D., Jr.
Rodriguez-Otero, P.
Manier, S.
Cavo, M.
Truppel-Hartmann, A.
Rowe, E.
Sanford, J.
Wang, J.
Campbell, T. B.
Jagannath, S.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 198 - 199
[10] Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis
Berdeja, Jesus G.
Raje, Noopur S.
Siegel, David S.
Lin, Yi
Anderson, Larry D., Jr.
Rodriguez-Otero, Paula
Manier, Salomon
Einsele, Hermann
Cavo, Michele
Truppel-Hartmann, Anna
Rowe, Everton
Sanford, Jill
Wang, Julie
Campbell, Timothy B.
Jagannath, Sundar
BLOOD, 2020, 136

← 1 2 3 4 5 →